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Abstract
Hepatoid gastric adenocarcinoma is a distinct variant of gastric carcinoma which represents a
comparatively small percentage of the disease and in many cases is producing high serum alpha-
fetoprotein (AFP). We report a case of an 85 year old woman who presented with epigastric and
right upper quadrant pain and was found in a CT scan to have multiple liver nodules and a gastric
antrum mass as well as an elevated AFP level of 155000 IU/ml. An endoscopic biopsy of the antral
mass showed hepatoid variant of gastric adenocarcinoma. The patient refused any further
treatment and died 4 months after diagnosis. Hepatoid gastric adenocarcinoma is considered to
have a poor prognosis, although cases with survival of several years have been reported. Poor
outcome in most of the cases is due to the fact that, as in our patient, metastatic disease is already
present at diagnosis.
Background
Hepatoid gastric adenocarcinoma is comparatively rare
and most case reports come from the Far East [1-4] while
reports from Europe and North America are fewer [1,5-9].
Although some authors estimate hepatoid type adenocar-
cinomas of the stomach to represent 1.3 to 15% of gastric
carcinomas, these percentages are, at least for western
countries, an overestimation and only a few hepatoid gas-
tric adenocarcinomas have been reported in the recent lit-
erature. AFP overproduction by these carcinomas happens
in most but not all the cases [1] and may help direct the
diagnosis in cases that it is elevated. In this case report, an
85 year old woman with an AFP-producing hepatoid type
gastric adenocarcinoma is described.
Case presentation
An 85 year-old woman presented with epigastric and right
upper quadrant abdominal pain of 3 days duration. The
patient had no relevant medical history, except for mild
hypertension and an excised squamous scin carcinoma of
the right hand 4 years previously. Review of systems dis-
closed weight loss of 5 kgs in 2 months but no hematem-
esis, hematochezia or melena. Physical examination was
positive for mildly anaemic sclerae. Laboratory investiga-
tion showed a hematocrit of 34% with hemoglobin of
11.5 g/dl, MCV of 113 fl and RDW of 13.5%. The AFP
level was very elevated at 155000 IU/ml. Other tumor
markers were normal. Hepatitis B and C panel was nega-
tive. An esophagogastroduodenoscopy revealed a gastric
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measure 7 cm and disclosed several liver metastases (Fig-
ure 1). Histopathologic examination of the antral mass
biopsy showed poorly differentiated adenocarcinoma
with hepatoid features. The carcinoma was composed of
polygonal tumor cells with abundant eosinophilic cyto-
plasm and round nuclei occasionally with obvious nucle-
oli and high mitotic activity. The tumor cells were
arranged mainly in a trabecular pattern while a smaller
area of glandular formations was also seen (Figure 2).
Some cells showed cytoplasmic mucin positive for PAS-
diastase (Periodic acid-Schiff-diastase) histochemical
stain. Immunohistochemically, the neoplastic cells
revealed diffuse positivity for a mixture of cytokeratins 8,
18 and 19. Many neoplastic cells interestingly showed
cytoplasmic positivity for a1-fetoprotein (Figure 3a).
Additionally, a "canalicular" pattern of staining was seen
with polyclonal carcinoembryonic antigen (CEA), which
is a characteristic hepatoid feature (Figure 3b). The tumor
cells were negative for the hepatocyte specific marker
hepatocyte paraffin-1 (Hep Par-1). These immunohisto-
chemical findings combined with the morphological fea-
tures described above, supported a diagnosis of hepatoid
variant of gastric adenocarcinoma. The patient and family
refused any treatment and returned home on oral analge-
tics as needed. She died of her disease 4 months after
admission.
Discussion
Gastric hepatoid adenocarcinoma (GHAC) with elevated
serum AFP, first described by Ishikura et al. 1985 [10], is
a rare gastric cancer subtype seen more frequently in older
patients, aged 60-70 years, with an elevation of serum AFP
level. The antrum of the stomach is the most common site
[1]. There are no specific symptoms and signs but gener-
ally, epigastric pain and fatigue are observed most fre-
quently [1]. Liver and lymph node metastases are
frequently found at diagnosis [11]. The primary tumor
usually appears as a large, necrotic and moderately vascu-
lar mass in CT scan [12]. Histopathologically, the tumor
is composed of two closely related areas, hepatoid-like
foci and adenocarcinomatous. Tumor cells in hepatoid
foci resemble the morphology of hepatocellular carci-
noma (HCC), and immunohistochemically can be posi-
tive for AFP, alpha-1 antitrypsin (AAT), alpha-1
antichymotrypsin (ACT) and albumin (ALB). Addition-
ally, polyclonal CEA shows a "canalicular" pattern of
staining which is a characteristic hepatoid feature. The
adenocarcinomatous component may be well or poorly
differentiated, often with clear cells and papillary pattern
[13,14].
Recently, glypican 3 (GPC3) has been evaluated as a sen-
sitive marker for AFP-producing gastric carcinoma (GC)
and its hepatoid component, and the authors support its
usefulness for identifying this aggressive subgroup of GC
[15]. Both the primary tumor and the metastatic liver
lesions of GHAC, when present, need to be differentiated
primarily from HCC. Generally, in HCC, neighboring cir-
rhotic lesions can be seen and tumor cells are positive for
Hep Par-1, a sensitive and specific immunohistochemical
marker for hepatocyte differentiation, whereas in meta-
static GHAC Hep Par-1 is often negative and neighboring
cirrhotic lesions are seldom seen [14]. P53 protein immu-
nohistochemical detection in GHAC has also been dem-
onstrated. In classic adenocarcinoma of the stomach, p53
protein is frequently expressed and often correlates with a
poor prognosis. In contrast, overexpression of p53 is a rare
Abdominal CT scan showing an antral tumor and liver metas-tasesFigure 1
Abdominal CT scan showing an antral tumor and 
liver metastases.
HistopathologyFigure 2
Histopathology. Poorly differentiated gastric adenocarci-
noma with hepatoid features, composed mainly of trabecular 
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of the palate, lung, and nasal epithelium carcinoma-asso-
ciated protein (PLUNC) immunostaining as a novel
marker that distinguishes GHAC from primary HCC [17].
However, the presence of markers of hepatoid differentia-
tion cannot be used as the sole diagnostic criteria for
GHAC but must always be accompanied by analogous
morphological patterns [18]. In differential diagnosis,
other AFP-producing gastric tumors as well as a metasta-
sizing germ cell tumor should also be excluded [9].
In terms of treatment, there are only sparse data in the lit-
erature pertaining specifically to GHAC and the disease
should be in general treated similarly to common gastric
adenocarcinoma. Surgical management of an early pri-
mary tumor, if feasible, is the indicated approach. Adju-
vant chemotherapy and radiotherapy should be given
according to current gastric cancer indications, despite the
fact that no specific data on adjuvant treatment of GHAC
are available. Palliative chemotherapy is the mainstay of
treatment in inoperable, recurrent or metastatic cases.
Concerning specific chemotherapy regimens, there are
again few data specific for this sub-type of cancer [1]. A
case report of an AFP-producing hepatoid gastric cancer
associated with multiple liver metastases that was success-
fully treated with paclitaxel-based chemotherapy has
recently been published [19].
Liver metastasectomy of completely resectable metastases
may be considered in selected cases. The first case of a
long-term (11 years) survival of AFP-producing gastric
cancer with successfully resected metachronous liver
metastasis and gastric remnant carcinoma has recently
been reported [20]. In such cases, long-term follow-up
and close observation are required to find any symptoms
of recurrence after gastrectomy, and early CT or MRI of
clinically suspect areas should be performed.
Conclusion
A multidisciplinary treatment approach modelled from
other types of cancer should be instituted to obtain opti-
mal results in hepatoid adenocarcinoma of the stomach.
Further investigation in the molecular pathogenesis of
hepatoid gastric adenocarcinoma is also of importance in
order to elucidate its origin and introduce novel treat-
ments.
Abbreviations
CT: computed tomography; MCV: mean corpuscular vol-
ume; RDW: red blood cell distribution width; MRI: mag-
netic resonance imaging.
Consent
Written informed consent was obtained from the patient
for publication of this case report and accompanying
HistopathologyFigure 3
Histopathology. a. Immunohistochemical cytoplasmic positivity for a1-fetoprotein, × 400. b. Immunohistochemical "canalicu-
lar" pattern of staining for polyclonal carcinoembryonic antigen (CEA), × 400 (arrows).Page 3 of 4
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